Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing

An accurate blood‐based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti‐EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmiegel, Wolff, Scott, Rodney J., Dooley, Susan, Lewis, Wendy, Meldrum, Cliff J., Pockney, Peter, Draganic, Brian, Smith, Steve, Hewitt, Chelsee, Philimore, Hazel, Lucas, Amanda, Shi, Elva, Namdarian, Kateh, Chan, Timmy, Acosta, Danilo, Ping‐Chang, Su, Tannapfel, Andrea, Reinacher‐Schick, Anke, Uhl, Waldemar, Teschendorf, Christian, Wolters, Heiner, Stern, Josef, Viebahn, Richard, Friess, Helmut, Janssen, Klaus‐Peter, Nitsche, Ulrich, Slotta‐Huspenina, Julia, Pohl, Michael, Vangala, Deepak, Baraniskin, Alexander, Dockhorn‐Dworniczak, Barbara, Hegewisch‐Becker, Susanne, Ronga, Philippe, Edelstein, Daniel L., Jones, Frederick S., Hahn, Stephan, Fox, Stephen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527457/
https://www.ncbi.nlm.nih.gov/pubmed/28106345
http://dx.doi.org/10.1002/1878-0261.12023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527457/
https://www.ncbi.nlm.nih.gov/pubmed/28106345
http://dx.doi.org/10.1002/1878-0261.12023

Ejemplares similares